Sir Paul Nurse and Sir Mark Walport formally open Kymab’s laboratories at Babraham Research Campus.
Kymab, a biopharmaceutical company developing a next generation human-mouse therapeutic antibody platform, today welcomed Sir Paul Nurse, President of the Royal Society and Sir Mark Walport, Director of the Wellcome Trust to formally open its Cambridge R&D facility.
"We are pleased with the progress that Kymab has made since its formation last year, and are proud to have provided technology and resources to build a substantial biopharmaceutical business focused on areas of unmet clinical need," said Sir Mark Walport, Director of the Wellcome Trust.
Kymab is developing its Kymouse™ technology at laboratories on the Babraham Research Campus, which it will use to discover novel monoclonal antibody-based medicines. Kymab announced that it plans to commence its therapeutic antibody drug discovery programmes using the Kymouse™ during 2011.
The company will initiate research programmes to address a broad range of disease targets in partnership with academic organisations and pharmaceutical companies.
"We are delighted to have our state-of-the-art facilities opened by Sir Paul and Sir Mark and are excited about advancing our research from Kymouse™ platform development to drug discovery during the year ahead,” said Andrew Sandham, Kymab Chairman & CEO.
Kymab was founded by Professor Allan Bradley, FRS, Director Emeritus of the Wellcome Trust Sanger Institute. He is a world leader in genome engineering using embryonic stem cells. The Kymouse™ will capture, in its engineered chromosomes, the entire diversity of the B lymphocyte component of the human immune system.
Kymab also announced the formation of its Scientific Advisory Board. Professor Terence Rabbitts, FRS chairs the Board which also includes Professor Douglas Fearon, FRS and Professor Bradley, FRS. The company also welcomed Volker Germaschewski, Jasper Clube and Mark Strivens to lead its antibody discovery, intellectual property and bioinformatics functions.